Open Payments

RONALD H YANAGIHARA

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
Where
GILROY, CA
NPI
1366478240
Received
$14,494 in 55 records, 2019 to 2025
As principal investigator
$99,418 of research payments to others in 41 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment5$365
2024General payment2$123
2023General payment6$111
2022General payment2$324
2021General payment17$6,125
2020General payment17$3,602
2019General payment6$3,841

By company

CompanyRecordsAmountYears
AstraZeneca Pharmaceuticals LP9$6,2462019–2025
Takeda Pharmaceuticals U.S.A., Inc.3$2,1472020
G1 Therapeutics, Inc.1$1,5002021
Blueprint Medicines Corporation2$1,4372020–2021
BeiGene, Ltd.1$1,3502021
EMD Serono, Inc.1$5002021
PFIZER INC.22$3542019–2021
Merck Sharp & Dohme LLC2$2022019
Novocure GmbH1$2002022
Janssen Biotech, Inc.3$1892021–2025
Janssen Scientific Affairs, LLC1$1022025
Exelixis Inc.3$1002019–2023
Daiichi Sankyo Inc.1$732025
Novartis Pharmaceuticals Corporation1$242023
Astellas Pharma US Inc1$242023
Eisai Inc.1$182023
Gilead Sciences, Inc.1$112021
Janssen Pharmaceuticals, Inc1$112020

By nature of payment

NatureRecordsAmount
Consulting Fee6$9,810
Honoraria3$3,006
Food and Beverage20$1,279
Education26$399

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-16Janssen Biotech, Inc.$146Food and BeverageIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-12-05Daiichi Sankyo Inc.$73Food and BeverageIn-kind items and services2025
2025-11-20Janssen Biotech, Inc.$25Food and BeverageIn-kind items and services2025
2025-11-12AstraZeneca Pharmaceuticals LP$17Food and BeverageIn-kind items and servicesLYNPARZA Drug, Oncology2025
2025-09-25Janssen Scientific Affairs, LLC$102Food and BeverageIn-kind items and servicesRYBREVANT Drug, Oncology2025
2024-11-05AstraZeneca Pharmaceuticals LP$17Food and BeverageIn-kind items and servicesENHERTU Biological, Oncology2024
2024-06-17AstraZeneca Pharmaceuticals LP$106Food and BeverageIn-kind items and services2024
2023-09-27AstraZeneca Pharmaceuticals LP$15Food and BeverageIn-kind items and servicesENHERTU Biological, Oncology2023
2023-08-21Eisai Inc.$18Food and BeverageCash or cash equivalentLenvima Drug, Oncology2023
2023-07-06Novartis Pharmaceuticals Corporation$24Food and BeverageIn-kind items and servicesLUTATHERA Drug, Oncology2023
2023-06-29AstraZeneca Pharmaceuticals LP$12Food and BeverageIn-kind items and servicesENHERTU Biological, Oncology2023
2023-05-16Exelixis Inc.$15Food and BeverageCash or cash equivalentCABOMETYX Drug, Oncology2023
2023-03-07Astellas Pharma US Inc$24Food and BeverageIn-kind items and servicesXtandi Drug, Oncology2023
2022-02-01AstraZeneca Pharmaceuticals LP$124Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2022
2022-01-19Novocure GmbH$200HonorariaCash or cash equivalent2022
2021-11-16PFIZER INC.$7EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2021
2021-10-31AstraZeneca Pharmaceuticals LP$2,397Consulting FeeCash or cash equivalent2021
2021-09-29PFIZER INC.$8EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2021
2021-09-28PFIZER INC.$12EducationIn-kind items and servicesIBRANCE Drug, ONCOLOGY2021
2021-09-15Janssen Biotech, Inc.$17Food and BeverageIn-kind items and services2021
2021-08-20G1 Therapeutics, Inc.$1,500HonorariaCash or cash equivalentCOSELA Drug, ONCOLOGY2021
2021-07-12Blueprint Medicines Corporation$130Food and BeverageIn-kind items and servicesGAVRETO Drug, Oncology / Rare Diseases2021
2021-07-05BeiGene, Ltd.$1,350Consulting FeeCash or cash equivalent2021
2021-06-22EMD Serono, Inc.$500Consulting FeeCash or cash equivalentTepmetko Drug, Oncology2021
2021-06-01Gilead Sciences, Inc.$11EducationIn-kind items and services2021
2021-04-15PFIZER INC.$124EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2021
2021-04-15PFIZER INC.$8EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2021
2021-04-13PFIZER INC.$13EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2021
2021-04-13PFIZER INC.$8EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2021
2021-03-24PFIZER INC.$13EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2021
2021-01-13PFIZER INC.$13EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2021
2021-01-13PFIZER INC.$8EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2021
2020-12-08Takeda Pharmaceuticals U.S.A., Inc.$1,068Consulting FeeCash or cash equivalentALUNBRIG Drug, ONCOLOGY2020
2020-12-08Takeda Pharmaceuticals U.S.A., Inc.$1,068Consulting FeeCash or cash equivalentALUNBRIG Drug, ONCOLOGY2020
2020-11-05PFIZER INC.$11EducationIn-kind items and servicesLORBRENA Drug, ONCOLOGY2020
2020-11-05PFIZER INC.$8EducationIn-kind items and servicesLORBRENA Drug, ONCOLOGY2020
2020-10-15Takeda Pharmaceuticals U.S.A., Inc.$9EducationIn-kind items and services2020
2020-10-08PFIZER INC.$13EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2020
2020-09-09Blueprint Medicines Corporation$1,306HonorariaCash or cash equivalent2020
2020-08-19PFIZER INC.$13EducationIn-kind items and servicesINLYTA Drug, ONCOLOGY2020
2020-02-19Janssen Pharmaceuticals, Inc$11EducationIn-kind items and servicesERLEADA Drug, Oncology2020
2020-02-13PFIZER INC.$13EducationIn-kind items and servicesXALKORI Drug, ONCOLOGY2020
2020-02-13PFIZER INC.$13EducationIn-kind items and servicesBRAFTOVI Drug, ONCOLOGY2020
2020-02-13PFIZER INC.$11EducationIn-kind items and servicesLORBRENA Drug, ONCOLOGY2020
2020-02-13PFIZER INC.$8EducationIn-kind items and servicesLORBRENA Drug, ONCOLOGY2020
2020-02-10PFIZER INC.$13EducationIn-kind items and servicesXALKORI Drug, ONCOLOGY2020
2020-02-10PFIZER INC.$11EducationIn-kind items and servicesLORBRENA Drug, ONCOLOGY2020
2020-02-10PFIZER INC.$8EducationIn-kind items and servicesLORBRENA Drug, ONCOLOGY2020
2020-01-15Exelixis Inc.$11EducationIn-kind items and servicesCabometyx Drug, Oncology2020
2019-11-18PFIZER INC.$11EducationIn-kind items and servicesLORBRENA Drug, ONCOLOGY2019
2019-07-12Merck Sharp & Dohme LLC$124Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2019
2019-03-10AstraZeneca Pharmaceuticals LP$3,425Consulting FeeCash or cash equivalentTAGRISSO Drug, Oncology2019
2019-02-01AstraZeneca Pharmaceuticals LP$129Food and BeverageIn-kind items and services2019
2019-02-01Merck Sharp & Dohme LLC$78Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2019
2019-01-31Exelixis Inc.$73Food and BeverageIn-kind items and servicesCabometyx Drug, Oncology2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2022-04-13Takeda Pharmaceuticals U.S.A., Inc.HAWAII PACIFIC HEALTH$3,000A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLAT2022
2022-04-13Takeda Pharmaceuticals U.S.A., Inc.HAWAII PACIFIC HEALTH$12,000A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLAT2022
2021-11-24ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$2,850Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-11-09ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$1,745Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-11-04Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$1002021
2021-11-04Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$8502021
2021-10-01Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$4902021
2021-09-23ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$300Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-09-20Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$2,0092021
2021-09-07ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$2,641Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-07-29ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$2,641Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-07-29ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$150Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-07-29ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$200Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-07-20ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$1,220Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-07-20Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$4902021
2021-07-01Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$2,0092021
2021-06-30ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$5,283Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-06-23ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$100Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-06-22ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$2,441Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-06-11ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$431Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-06-03ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$9,158Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-05-20ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$250Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-04-30ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$3,962Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-04-26ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$150Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-03-30ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$4,235Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-03-04ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$50Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-03-02ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$4,160Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-02-24ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$1,875Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-02-17ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$597Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-01-25Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$4902021
2021-01-07ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$475Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-01-07ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$597Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-01-07ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$3,923Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-2021
2021-01-06Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$2,1002021
2021-01-06Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$2,2332021
2021-01-06Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$2672021
2020-10-13ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$1,100M14-2392020
2020-10-13ABBVIE INC.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$11,200M14-2392020
2020-06-23Chiesi USA, Inc.HAWAI I PACIFIC HEALTH$6,500CUSA-081-HEM-012020
2019-10-17Genentech, Inc.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$1,500PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC2019
2019-06-03Genentech, Inc.HAWAII PACIFIC HEALTH RESEARCH INSTITUTE$3,636PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Santa Clara CountyGilroy city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Gilroy, CA, county Santa Clara County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Gilroy, CA
County
Santa Clara County, CA
State
California
Population B0100359,0041,902,04739,287,377
Population, 2020 census P159,5201,936,25939,538,223
Median age B0100237.038.137.9
Under 18 B0100126.8%20.5%22.0%
65 and over B0100113.0%14.8%15.7%
Households B1100117,459659,35313,548,091
Foreign born B0500224.3%41.5%27.0%
Median household income B19013$133,107$164,281$99,122
Median family income B19113$142,150$187,890$113,346
Per capita income B19301$48,965$80,312$49,513
Poverty rate B170016.7%7.1%12.0%
Unemployment rate B230256.3%4.9%6.6%
Civilian labor force B2302530,2691,050,46820,068,466
Mean commute (minutes) B0801333.326.228.7
Bachelor's degree or higher B1500329.3%56.5%37.1%
Housing units B2500118,054698,83714,644,735
Owner-occupied B2500362.4%55.1%55.9%
Renters B2500337.6%44.9%44.1%
Median home value B25077$1,027,400$1,490,600$734,700
Median gross rent B25064$2,301$2,857$2,036
White, not Hispanic B0300224.3%27.2%33.8%
Black B030021.8%2.2%5.2%
Hispanic or Latino B0300258.9%25.0%40.2%
Asian B030029.3%40.3%15.3%
American Indian and Alaska Native B030020.0%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Gilroy, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.